Anthelio Healthcare Solutions

antheliohealth.com

Anthelio is now Atos. Anthelio is the largest independent provider of healthcare technology solutions in the market. We offer solutions across the spectrum of care, providing customers the ability to solve their critical technology needs from a single source while delivering cost savings and efficiencies. Our end-to-end solutions include IT infrastructure services, IT applications management, EHR optimization, Patient Engagement, Analytics, and Revenue Cycle Management (RCM) including HIM Services, Patient Financial Services and Cancer Registry Services. Anthelio drives sustainable value to over 63,000 physicians and nurses in hundreds of healthcare organizations supporting their annual revenue of over $67 billion and impacting quality care to over 60 million patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO STUDY PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

Phio Pharmaceuticals Corp. | December 22, 2022

news image

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intrat...

Read More

Business Insights, PHARMA TECH

WEST EXPANDS COLLABORATION WITH CORNING AND INTRODUCES FIRST PRODUCT

West Pharmaceutical Services | February 13, 2023

news image

West Pharmaceutical Services, Inc., a leading global innovative injectable drug administration solutions provider, recently announced the expansion of its remarkable collaboration with Corning Incorporated, which now includes exclusive distribution rights for Corning Valor® Glass vials as well as the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials employing SG EZ-fill® technology. The West Ready Pack™ with Corning Valor® RT...

Read More

Business Insights, PHARMA TECH

FLEXAN TO COLLABORATE WITH KSE SCIENTIFIC TO BRING EXPANDED MEDICAL DEVICE CAPABILITIES TO MARKET

Prnewswire | April 13, 2023

news image

Flexan LLC announced that it is expanding its services to include custom manufacturing of sterile liquids and custom formulated solutions for a variety of medical device applications. Flexan is partnering with its parent company, ILC Dover, and its KSE Scientific division to expand offerings to its medical device customers. KSE Scientific provides standard and custom formulations and packaging while following the most stringent quality standards. The company is FDA registered for medical d...

Read More

WEBINAR HOSTED BY XTALKS TO COVER ACTIONS PHARMACEUTICAL COMMERCIAL TEAMS CAN TAKE TO STAY ON TRACK WITH 2020 GOALS

Xtalks | July 08, 2020

news image

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...

Read More
news image

Business Insights, PHARMACY MARKET

PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO STUDY PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

Phio Pharmaceuticals Corp. | December 22, 2022

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intrat...

Read More
news image

Business Insights, PHARMA TECH

WEST EXPANDS COLLABORATION WITH CORNING AND INTRODUCES FIRST PRODUCT

West Pharmaceutical Services | February 13, 2023

West Pharmaceutical Services, Inc., a leading global innovative injectable drug administration solutions provider, recently announced the expansion of its remarkable collaboration with Corning Incorporated, which now includes exclusive distribution rights for Corning Valor® Glass vials as well as the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials employing SG EZ-fill® technology. The West Ready Pack™ with Corning Valor® RT...

Read More
news image

Business Insights, PHARMA TECH

FLEXAN TO COLLABORATE WITH KSE SCIENTIFIC TO BRING EXPANDED MEDICAL DEVICE CAPABILITIES TO MARKET

Prnewswire | April 13, 2023

Flexan LLC announced that it is expanding its services to include custom manufacturing of sterile liquids and custom formulated solutions for a variety of medical device applications. Flexan is partnering with its parent company, ILC Dover, and its KSE Scientific division to expand offerings to its medical device customers. KSE Scientific provides standard and custom formulations and packaging while following the most stringent quality standards. The company is FDA registered for medical d...

Read More
news image

WEBINAR HOSTED BY XTALKS TO COVER ACTIONS PHARMACEUTICAL COMMERCIAL TEAMS CAN TAKE TO STAY ON TRACK WITH 2020 GOALS

Xtalks | July 08, 2020

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us